Composition and method for topical treatment of tar-responsive dermatological disorders 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2007103687 A2 2007-09-13 [WO2007103687]WO2007103687 A3 2008-12-11 [WO2007103687] / 2007-09-132008-12-11
申请号/申请日
2007WO-US62975 / 2007-02-28
发明人
YU RUEY J;VAN SCOTT EUGENE J;LEE YALING;
申请人
TRISTRATA;
主分类号
IPC分类号
A01N-065/00
摘要
(WO2007103687) The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatological disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.  The invention also relates to a method of treating a tar-responsive dermatological disorder by topically applying the composition to skin of a mammal, preferably a human, that is involved with the disorder.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2006US-60778128 2006-03-01
主权利要求
(WO2007103687) CLAIMS We claim 1 A composition comprising a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatological disorder, the composition being in a liquid or light gel form when at a temperatuie selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal 2 The composition of claim 1 , wherein the tar is selected from the group consisting of coal tar, wood tar and shale tar 3 The composition of claim 1 , wherein the tar is coal tar 4 The composition of claim 1 , wherein the tar is liquor carboms detergens 5 The composition of claim 1 , wherein the tar is a solution of the tar in an anhydrous solvent 6 The composition of claim 5, wherein the anhydrous solvent is selected from the group consisting of at least one of ethanol, isopropyl alcohol, cyclomettucone, propylene glycol, butylene glycol, dusopropyl adipate, diethyl tartarate, tπethyl citrate, tπpropyl citrate, tπisopropyl citrate, isopropyl myπstate, isopropyl palmitate, ethoxy diglycol, isododecane, isohexadecane or isoeicosane 7 The composition of claim 1 , wherein the wax is selected from the group consisting of at least one of dioctyldodecyl dodecanedioate (DIADD), dnsocetyl dodecanedioate (DICDD), octyldodecyl PPG-3 myπstyl ether dimer dilinoleate (PoIyEFA), stearyl/PPG-3 myπstyl ether dimer dilinoleate (PoIyIPL), dioctyldodecyl dimer dilinoleate (DI-EFA), diisostearyl adipate (DISA), dicetearyl dimer dilinoleate (IPL), cetyl ester wax (synthetic spermaceti), mineral oil, dimethicone, apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, ceresm, jojoba wax, lanolin wax, mink wax, montan wax, orange peel wax, ouπcury wax, ozokeπte, palm kernel wax, paraffin, polyethylene glycol (PEG)-beeswax, PEG-carnauba wax, πce wax, shellac wax, spent gram wax, synthetic beeswax, and synthetic Japan wax 8. The composition of claim 6, wherein the wax is a liquid wax selected from the group consisting of at least one of DIADD, DICDD, PoIyEFA, PoIyIPL, DI-EFA, DISA and IPL. 9. The composition of claim 1, further comprising at least one of a nonionic surfactant and a film former. 10. The composition of claim 9, wherein the nonionic surfactant is selected from the group consisting of at least one of a sorbitan fatty acid ester; a polyoxyethylene derivative of a sorbitan fatty acid ester; a polyoxyethylene fatty glyceride; a polyoxyethylene polyol fatty acid esters; and a polyoxyethylene fatty ether. 11. The composition of claim 10, wherein the sorbitan fatty acid ester is selected from the group consisting of sorbitan laurate, sorbitan palmitate, sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate and sorbitan trioleate. 12. The composition of claim 10, wherein the polyoxyethylene derivative of a sorbitan fatty acid ester is selected from the group consisting of polysorbate 20, polysorbate 21, PEG-80 sorbitan laurate, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85. 13. The composition of claim 10, wherein the polyoxyethylene fatty glyceride is selected from the group consisting of PEG-25 hydrogenated castor oil, PEG-40 hydrogenated castor oil, polyoxyethylene 7 hydrogenated castor oil and polyoxyethylene 40 hydrogenated castor oil. 14. The composition of claim 10, wherein the polyoxyethylene polyol fatty acid ester is polyoxyethylene 40 sorbitol septaoleate. 15. The composition of claim 9, wherein the film former is selected from the group consisting of at least one copolymer of vinylpyrrolidone (PVP) and a long-chain alpha-olefin, a polyurethane, a vinylcaprolactam/ vinylpyrrolidone (VP)/dimethylaminoethyl methacrylate copolymer, a vinyl acetate (VA)/butyl maleate/isobornyl acrylate copolymer, a vinylcaprolactam/VP/dimethylaminoethyl methacrylate copolymer, a monoethyl ester of a copolymer of methyl vinyl ether and maleic anhydride (PVM/MA copolymer), a PVP/vinylcaprolactam/dimethylaminopropyl methacrylamide acrylate, an isobutylene/ethylmaleimide/hydroxyethylmaleimide copolymer, a monoalkyl ester of poly (methyl vinyl ether/maleic acid), a vmylpyrrohdone/vmyl acetate copolymer, a dimethiconol, a dimethiconol-dimethicone copolyol, cellulose and a cellulose derivative. 16. The composition of claim 15, wherein the copolymer of vinylpyrrolidone (PVP) and a long-chain alpha-olefin is selected from the group consisting of butylated PVP, vinylpyrrolidone (VP)/hexadecene copolymer, VP/eicosene copolymer and tricontanyl PVP. 17. The composition of claim 15, wherein the monoalkyl ester of poly (methyl vinyl ether/maleic acid) is selected from the group consisting of ethyl ester of PVM/MA copolymer, butyl ester of PVM/MA copolymer and isopropyl ester of PVM/MA copolymer. 18. The composition of claim 15, wherein the cellulose denvative is selected from the group consisting of cellulose acetate, cellulose tπacetate, nitrocellulose, ethyl cellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl methyl cellulose and microcystalline cellulose. 19. The composition of claim 1 , wherein the light gel form of the composition comprises a gelling agent selected from the group consisting of chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, a polyquaternmm compound, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, a carbomer and ammoniated glycyrrhizinate. 20. The composition of claim 1 , wherein the tar is present in an amount of about 0.1 % to about 99%, the wax is present in an amount of about 1% to about 50%, and when the composition is in the form of a light gel, the composition further comprises a gelling agent present in an amount of about 0.1% to about 5%, all amounts being percent by weight. 21 The composition of claim 20, further comprising at least one of a nonionic surfactant and a film former, wherein the nonionic surfactant, when present, is present in an amount of about 1% to about 40%, and the film former, when present, is present in an amount of about 1% to about 30%, all amounts being percent by weight. 22. The composition of claim 21, wherein the tar is present in an amount of about 1% to about 30%, the wax is present in an amount of about 1% to about 25%, when the composition is in the form of a light gel, the composition further comprises a gelling agent present in an amount of about 0.1% to about 0.5%, wherein the nonionic surfactant, when present, is present in an amount of about 1% to about 25%, and the film former, when present, is present in an amount of about 1% to about 20%, all amounts being percent by weight. 23. The composition of claim 22, wherein the tar is present in an amount of about 5% to about 20%, the wax is present in an amount of about 2% to about 10%, the nonionic surfactant, when present, is present in an amount of about 2% to about 15%, and the film former, when present, is present in an amount of about 1% to about 10%, all amounts being percent by weight. 24. The composition of claim 1, further comprising at least one topically active pharmaceutical or cosmetic agent or at least one separate composition comprising at least one topically active pharmaceutical or cosmetic agent for a synergetic or synergistic effect. 25. The composition of claim 24, wherein the topically active pharmaceutical or cosmetic agent is selected from the group consisting of one or more of a hydroxyacid, polyhydroxy acid, polyhydroxy lactone, ketoacid and related compounds; phenyl alpha acyloxyalkanoic acid and derivatives; N-acyl-aldosamines, N-acylamino acids and related N-acyl compounds; N- (phosphonoalkyl)-aminocarbohydrates, N-(phosphonoalkyl)-amino acids and their related N- (phosphonoalkyl)-compounds; local analgesic, local anesthetic; anti-acne agent; anti-bacterial agent; anti-yeast agent; anti-fungal agent; anti-viral agent; anti-infective agent; anti-dandruff agent; anti- dermatitis agent; anti-eczema agent; anti-histamine agent; anti-pruritic agent; anti-emetic; anti- motion sickness agent; anti-inflammatory agent; anti-hyperkeratotic agent; antiperspirant; anti- psoriatic agent; anti-rosacea agent; anti-seborrheic agent; hair conditioner, hair treatment agent; anti- aging agent, anti-wrinkle agent; anti-anxiety agent; anti-convulsant agent; anti-depressant agent; sunblock agent, sunscreen agent; skin lightening agent; depigmenting agent; astringent; cleansing agent; corn, callus or wart removing agent; skin plumping agent; skin volumizing agent; skin firming agent; matrix metalloproteinase (MMP) inhibitor; topical cardiovascular agent; wound- healing agent; gum disease or oral care agent; amino acid; peptide; dipeptide; tripeptide; glutathione and its derivatives; oligopeptide; polypeptide; carbohydrate; aminocarbohydrate; vitamin; corticosteroid; tanning agent; hormone and retinoid. 26. The composition of claim 24, wherein the topically active pharmaceutical or cosmetic agent is selected from the group consisting of one or more of abacavir, acebutolol, acetaminophen, acetaminosalol, acetazolamide, acetohydroxamic acid, acetylsalicylic acid, N-acylglutathione ethyl ester and other esters, N-acyl proline ethyl ester and other esters, acitretin, aclovate, acrivastine, actiq, acyclovir, adalimumab, adapalene, adefovir dipivoxil, adenosine, albuterol, alefacept, alfuzosin, allopurinol, alloxanthine, almotπptan, alprazolam, alprenolol, aluminum acetate, aluminum chloride, aluminum chlorohydroxide, aluminum hydroxide, amantadine, amiloride, aminacrine, />-aminobenzoic acid, aminocaproic acid, aminolevulinic acid, aminosalicylic acid, amiodarone, amitπptylme, amlodipine, amocarzme, amodiaquin, amorolfine, amoxapine, amphetamine, ampicillin, anagrelide, anastrozole, anthralin, apomorphine, aprepitant, arbutin, aripiprazole, ascorbic acid, ascorbyl palmitate, atazanavir, atenolol, atomoxetine, atropine, azathioprine, azelaic acid, azelastine, azithromycin, bacitracin, beclomethasone dipropionate, bemegride, benazepril, benzilic acid, bendroflumethiazide, benzocaine, benzonatate, benzophenone, benzoyl peroxide, benztropine, bepridil, betamethasone dipropionate, betamethasone valerate, brimonidine, brompheniramine, bupivacaine, buprenorphine, bupropion, burimamide, butenafine, butoconazole, cabergoline, caffeic acid, caffeine, calcipotriene, camphor, candesartan cilexetil, capsaicin, carbamazepine, carbamide peroxide, cefditoren pivoxil, cefepime, cefpodoxime proxetil, celecoxib, cetirizine, cevimeline, chitosan, chlordiazepoxide, chlorhexidine, chloroquine, chlorothiazide, chloroxylenol, chlorpheniramine, chlorpromazine, chlorpropamide, ciclopirox, cilostazol, cimetidine, cinacalcet, ciprofloxacin, citalopram, citric acid, cladribine, clarithromycin, clemastine, clindamycin, clioquinol, clobetasol propionate, clocortolone pivalate, clomiphene, clonidine, clopidogrel, clotrimazole, clozapine, cocaine, codeine, cromolyn, crotamiton, cyclizine, cyclobenzaprine, cycloserine, cytarabine, dacarbazine, dalfopristin, dapsone, daptomycin, daunorubicin, deferoxamine, dehydroepiandrosterone, delavirdine, desipramine, desloratadine, desmopressin, desoximetasone, dexamethasone, dexmedetomidine, dexmethylphenidate, dexrazoxane, dextroamphetamine, diazepam, diclofenac, dicyclomine, didanosine, dihydrocodeine, dihydromorphine, diltiazem, 6,8-dimercaptooctanoic acid (dihydrolipoic acid), diphenhydramine, diphenoxylate, dipyridamole, disopyramide, dobutamine, dofetilide, dolasetron, donepezil, dopa esters, dopamide, dopamine, dorzolamide, doxepin, doxorubicin, doxycycline, doxylamine, doxypin, duloxetine, dyclonine, econazole, efalizumab, eflornithine, eletriptan, emtricitabine, enalapril, ephedrine, epinephrine, epinine, epirubicin, eptifibatide, ergotamine, erythromycin, escitalopram, esmolol, esomeprazole, estazolam, estradiol, etanercept, ethacrynic acid, ethinyl estradiol, ethyl pyruvate, etidocaine, etomidate, famciclovir, famotidine, felodipine, fentanyl, ferulic acid, fexofenadine, flecainide, fluconazole, flucytosine, fluocinolone acetonide, fluocinonide, 5- fluorouracil, fluoxetine, fluphenazine, flurazepam, fluticasone propionate, fluvoxamine, formoterol, furosemide, galactarolactone, galactonic acid, galactonolactone, galantamme, gatifloxacin, gefitmib, gemcitabine, gemifloxacin, glucarolactone, gluconic acid, gluconolactone, glucuronic acid, glucuronolactone, glycolic acid, gπseofulvin, guaifenesin, guanethidine, N-guanylhistamine, halopendol, haloprogin, hexylresorcinol, homatropme, homosalate, hydralazine, hydrochlorothiazide, hydrocortisone, hydrocortisone 21 -acetate, hydrocortisone 17-butyrate, hydrocortisone 17-valerate, hydrogen peroxide, hydromoφhone, hydroqumone, hydroquinone monoether, hydroxyzine, hyoscyamine, hypoxanthine, lbuprofen, ichthammol, idarubicin, imatinib, lmipramme, imiquimod, indinavir, mdomethacin, infliximab, lrbesartan, lrinotecan, lsoetharine, isoproterenol, itraconazole, kanamycin, ketamine, ketanseπn, ketoconazole, ketoprofen, ketotifen, kojic acid, labetalol, lactic acid, lactobionic acid, lamivudine, lamotngine, lansoprazole, letrozole, leuprolide, levalbuterol, levofloxacm, hdocame, hnezolid, lobehne, loiatadme, loperamide, losartan, loxapme, lysergic diethylamide, mafenide, malic acid, maltobionic acid, mandelic acid, maprotiline, mebendazole, mecamylamine, meclizine, meclocycline, memantine, menthol, meperidine, mepivacaine, mequmol, mercaptopurine, mescaline, metanephrme, metaproterenol, metaraminol, metformin, methadone, methamphetamine, methotrexate, methoxamine, methyldopa esters, methyldopamide, 3,4-methylenedioxymethainphetamine, methyllactic acid, methyl nicotinate, methylphenidate, methyl salicylate, metiamide, metolazone, metoprolol, metronidazole, mexiletine, miconazole, midazolam, midodrine, miglustat, minocycline, minoxidil, mirtazapine, mitoxantrone, moexipπlat, molindone, monobenzone, morphine, moxifloxacin, moxonidine, mupirocin, nadolol, naftifine, nalbuphine, nalmefene, naloxone, naproxen, nefazodone, nelfinavir, neomycin, nevirapine, nicardipine, nicotine, nifedipine, nimodipme, nisoldipine, nitrofurantoin, nizatidine, norepinephπne, nystatin, octopamine, octreotide, octyl methoxycinnamate, octyl salicylate, ofloxacin, olanzapine, olmesartan medoxomil, olopatadine, omeprazole, ondansetron, oxiconazole, oxotremorine, oxybenzone, oxybutynin, oxycodone, oxymetazoline, padimate O, palonosetron, pantothenic acid, pantoyl lactone, paroxetine, pemoline, penciclovir, penicillamine, penicillins, pentazocine, pentobarbital, pentostatin, pentoxifylline, pergolide, perindopril, permethrin, phencyclidine, phenelzine, pheniramme, phenmetrazme, phenobarbital, phenol, phenoxybenzamme, phentolamine, phenylephrine, phenylpropanolamine, phenytoin, N-(phosphonomethyl)-glycine, N- (phosphonomethyl)-creatme, N-(phosphonomethyl)-tyramine, physostigmine, pilocarpine, pimecrolimus, pimozide, pindolol, pioglitazone, pipamazine, piperonyl butoxide, pirenzepine, podofilox, podophyllin, povidone iodine, pramipexole, pramoxme, prazosin, prednisone, prenalterol, pπlocaine, procainamide, procaine, procarbazine, praline, promazine, promethazine, promethazine propionate, propafenone, propoxyphene, propranolol, propylthiouracil, protπptyhne, pseudoephednne, pyrethrm, pyrilamine, pynmethamine, quetiapine, quinapril, qumethazone, quimdine, quinupπstin, rabeprazole, reserpine, resorcinol, tetmal, 13-cis retmoic acid, retinoic acid, retinol, retinyl acetate, retinyl palmitate, πbaviπn, ribonic acid, πbonolactone, πfampin, πfapentine, nfaximm, riluzole, nmantadme, risedronic acid, risperidone, ntodrme, nvastigmme, nzatπptan, ropinirole, ropivacaine, salicylamide, salicylic acid, salmeterol, scopolamine, selegiline, selenium sulfide, serotonin, sertaconazole, sertindole, sertraline, shale tar, sibutramme, sildenafil, sotalol, streptomycin, strychnine, sulconazole, sulfacetamide, sulfabenz, sulfabenzamide, sulfabromomethazine, sulfacetamide (sodium sulfacetamide), sulfachlorpyπdazine, sulfacytine, sulfadiazine, sulfadimethoxine, sulfadoxine, sulfaguanole, sulfalene, sulfamethizole, sulfamethoxazole, sulfanilamide, sulfapyrazine, sulfapyridine, sulfasalazine, sulfasomizole, sulfathiazole, sulfisoxazole, sulfur, tacrolimus, tadalafil, tamsulosin, tartaric acid, tazarotene, tegaserol, telithromycm, telmisartan, temozolomide, tenofovir disoproxil, terazosin, terbmafine, terbutahne, terconazole, terfenadine, tetracaine, tetracycline, tetrahydrozolme, thalidomide, theobromine, theophylline, thiabendazole, thioctic acid (hpoic acid), thioridazine, thiothixene, thymol, tiagabine, timolol, tinidazole, tioconazole, tirofiban, tizanidme, tobramycin, tocainide, tolazoline, tolbutamide, tolnaftate, tolterodine, tramadol, tranylcypromine, trazodone, tπamcmolone acetonide, triamcinolone diacetate, triamcinolone hexacetomde, triamterene, triazolam, tnclosan, tπflupromazine, trimethoprim, tπmipramine, tπpelennamme, tπprohdine, tromethamine, tropic acid, tyramine, undecylemc acid, urea,  urocanic acid, ursodiol, vardenafil, venlafaxme, verapamil, vitamin E acetate, voπconazole, warfarin, wood tar, xanthine, zafirlukast, zaleplon, zinc pyπthione, ziprasidone, zolmitπptan or Zolpidem 27 The composition of claim 1 , wherein the tar is a liquid tar solution that has been treated with activated carbon whereby the composition does not stain skin or clothing 28 The composition of claim 1, wherein the dermatological disorder is selected from the group consisting of psonasis, eczema, atopic dermatitis, seborrheic dermatitis and pruritus 29 A method of treating a tar-responsive dermatological disorder in a mammal comprising topically applying a tar composition compπsing a wax and a therapeutically effective amount of tar to skin of the mammal involved in the disorder, the composition being in liquid or light gel form at a temperature selected from room temperature and skin temperature of the mammal. 30. The method of claim 29, wherein the mammal is a human. 31. The method of claim 30, wherein the tar is a liquid tar solution that has been treated with activated carbon whereby the composition does not stain skin or clothing. 32. The method of claim 29, wherein the tar is selected from the group consisting of coal tar, wood tar and shale tar. 33. The method of claim 29, wherein the tar is coal tar. 34. The method of claim 29, wherein the tar is liquor carbonis detergens. 35. The method of claim 29, wherein the tar is a solution of the tar in an anhydrous solvent. 36. The method of claim 35, wherein the anhydrous solvent is selected from the group consisting of at least one of ethanol, isopropyl alcohol, cyclomethicone, propylene glycol, butyl ene glycol, diisopropyl adipate, diethyl tartarate, triethyl citrate, tripropyl citrate, triisopropyl citrate, isopropyl myristate, isopropyl palmitate, ethoxy diglycol, isododecane, isohexadecane or isoeicosane. 37. The method of claim 29, wherein the wax is selected from the group consisting of at least one of dioctyldodecyl dodecanedioate (DIADD), diisocetyl dodecanedioate (DICDD), octyldodecyl PPG-3 myristyl ether dimer dilinoleate (PoIyEFA), stearyl/PPG-3 myristyl ether dimer dilinoleate (PoIyIPL), dioctyldodecyl dimer dilinoleate (DI-EFA), diisostearyl adipate (DISA), dicetearyl dimer dilinoleate (IPL), cetyl ester wax (synthetic spermaceti), mineral oil, dimethicone, apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, ceresin, jojoba wax, lanolin wax, mink wax, montan wax, orange peel wax, ouricury wax, ozokerite, palm kernel wax, paraffin, polyethylene glycol (PEG)-beeswax, PEG-carnauba wax, rice wax, shellac wax, spent grain wax, synthetic beeswax, and synthetic Japan wax. 38. The method of claim 37, wherein the wax is a liquid wax selected from the group consisting of at least one of DIADD, DICDD, PoIyEFA, PoIyIPL, DI-EFA, DISA and IPL. 39. The method of claim 29, further comprising at least one of a nonionic surfactant and a film former. 40. The method of claim 39, wherein the nonionic surfactant is selected from the group consisting of at least one of a sorhitan fatty acid ester; a polyoxyethylene derivative of a sorbitan fatty acid ester; a polyoxyethylene fatty glyceride; a polyoxyethylene polyol fatty acid esters; and a polyoxyethylene fatty ether. 41. The method of claim 40, wherein the sorbitan fatty acid ester is selected from the group consisting of sorbitan laurate, sorbitan palmitate, sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate and sorbitan trioleate. 42. The method of claim 40, wherein the polyoxyethylene derivative of a sorbitan fatty acid ester is selected from the group consisting of polysorbate 20, polysorbate 21, PEG-80 sorbitan laurate, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85. 43. The method of claim 40, wherein the polyoxyethylene fatty glyceride is selected from the group consisting of PEG-25 hydro genated castor oil, PEG-40 hydro genated castor oil, polyoxyethylene 7 hydrogenated castor oil and polyoxyethylene 40 hydrogenated castor oil. 44. The method of claim 40, wherein the polyoxyethylene polyol fatty acid ester is polyoxyethylene 40 sorbitol septaoleate. 45. The method of claim 39, wherein the film former is selected from the group consisting of at least one copolymer of vinylpyrrolidone (PVP) and a long-chain alpha-olefin, a polyurethane, a vinylcaprolactam/ vinylpyrrolidone (VP)/dimethylaminoethyl methacrylate copolymer, a vinyl acetate (VA)/butyl maleate/isobornyl acrylate copolymer, a vinylcaprolactam/VP/dimethylaminoethyl methacrylate copolymer, a monoethyl ester of a copolymer of methyl vinyl ether and maleic anhydride (PVM/MA copolymer), a PVP/vinylcaprolactam/dimethylaminopropyl methacrylamide acrylate, an isobutylene/ethylmaleimide/hydroxyethylmaleimide copolymer, a monoalkyl ester of poly (methyl vinyl ether/maleic acid), a vinylpyrrolidone/vinyl acetate copolymer, a dimethiconol, a dimcthiconol-dimethicone copolyol, cellulose and a cellulose derivative. 46. The method of claim 45, wherein the copolymer of vinylpyrrolidone (PVP) and a long- chain alpha-olefm is selected from the group consisting of butylated PVP, vinylpyrrolidone (VP)/hexadecene copolymer, VP/eicosene copolymer and tricontanyl PVP. 47. The method of claim 45, wherein the monoalkyl ester of poly (methyl vinyl ether/maleic acid) is selected from the group consisting of ethyl ester of PVM/MA copolymer, butyl ester of P VM/MA copolymer and isopropyl ester of PVM/MA copolymer. 48. The method of claim 45, wherein the cellulose derivative is selected from the group consisting of cellulose acetate, cellulose triacetate, nitrocellulose, ethylcellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl methyl cellulose and microcystalline cellulose. 49. The method of claim 29, wherein the light gel form of the composition comprises a gelling agent selected from the group consisting of chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, a polyquaternium compound, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, a carbomer and ammoniated glycyrrhizinate. 50. The method of claim 29, wherein the tar is present in an amount of about 0.1 % to about 99%, the wax is present in an amount of about 1% to about 50%, and when the composition is in the form of a light gel, the composition further comprises a gelling agent present in an amount of about 0.1% to about 5%, all amounts being percent by weight. 51. The method of claim 50, further comprising at least one of a nonionic surfactant and a film former, wherein the nonionic surfactant, when present, is present in an amount of about 1% to about 40%, and the film former, when present, is present in an amount of about 1% to about 30%, all amounts being percent by weight. 52. The method of claim 51, wherein the tar is present in an amount of about 1% to about 30%, the wax is present in an amount of about 1% to about 25%, when the composition is in the form of a light gel, the composition further comprises a gelling agent present in an amount of about 0.1% to about 0.5%, wherein the nonionic surfactant, when present, is present in an amount of about 1% to about 25%, and the film former, when present, is present in an amount of about 1% to about 20%, all amounts being percent by weight. 53. The method of claim 52, wherein the tar is present in an amount of about 5% to about 20%, the wax is present in an amount of about 2% to about 10%, the nonionic surfactant, when present, is present in an amount of about 2% to about 15%, and the film former, when present, is present in an amount of about 1% to about 10%, all amounts being percent by weight. 54. The method of claim 29, wherein the method further comprises topically applying for a synergetic or synergistic effect as part of the composition or separately in conjunction with the composition at one topically active pharmaceutical or cosmetic agent or at least one separate composition comprising at least one topically active pharmaceutical or cosmetic agent. 55. The method of claim 54, wherein the topically active pharmaceutical or cosmetic agent is selected from the group consisting of one or more of a hydroxyacid, polyhydroxy acid, polyhydroxy lactone, ketoacid and related compounds; phenyl alpha acyloxyalkanoic acid and derivatives; N-acyl-aldosamines, N-acylamino acids and related N-acyl compounds; N- (phosphonoalkyl)-aminocarbohydrates, N-(phosphonoalkyl)-amino acids and their related N- (phosρhonoalkyl)-compounds; local analgesic, local anesthetic; anti-acne agent; anti-bacterial agent; anti-yeast agent; anti-fungal agent; anti-viral agent; anti-infective agent; anti-dandruff agent; anti- dermatitis agent; anti-eczema agent; anti-histamine agent; anti-pruritic agent; anti-emetic; anti- motion sickness agent; anti-inflammatory agent; anti-hyperkeratotic agent; antiperspirant; anti- psoriatic agent; anti-rosacea agent; anti-seborrheic agent; hair conditioner, hair treatment agent; anti- aging agent, anti-wrinkle agent; anti-anxiety agent; anti-convulsant agent; anti-depressant agent; sunblock agent, sunscreen agent; skin lightening agent; depigmenting agent; astringent; cleansing agent; corn, callus or wart removing agent; skin plumping agent; skin volumizing agent; skin firming agent; matrix metalloproteinase (MMP) inhibitor; topical cardiovascular agent; wound- healing agent; gum disease or oral care agent; amino acid; peptide; dipeptide; tripeptide; glutathione and its derivatives; oligopeptide; polypeptide; carbohydrate; aminocarbohydrate; vitamin; corticosteroid; tanning agent; hormone and retinoid. 56. The method of claim 54, wherein the topically active pharmaceutical or cosmetic agent is selected from the group consisting of one or more of abacavir, acebutolol, acetaminophen, acetaminosalol, acetazolamide, acetohydroxamic acid, acetylsalicylic acid, N-acylglutathione ethyl ester and other esters, N-acyl proline ethyl ester and other esters, acitretin, aclovate, acrivastine, actiq, acyclovir, adalimumab, adapalene, adefovir dipivoxil, adenosine, albuterol, alefacept, alfuzosin, allopurinol, alloxanthine, almotriptan, alprazolam, alprenolol, aluminum acetate, aluminum chloride, aluminum chlorohydroxide, aluminum hydroxide, amantadine, amiloride, aminacrine, /?-aminobenzoic acid, aminocaproic acid, aminolevulinic acid, aminosalicylic acid, amiodarone, amitriptyline, amlodipine, amocarzine, amodiaquin, amorolfine, amoxapine, amphetamine, ampicillin, anagrelide, anastrozole, anthralin, apomorphine, aprepitant, arbutin, aripiprazole, ascorbic acid, ascorbyl palmitate, atazanavir, atenolol, atomoxetine, atropine, azathioprine, azelaic acid, azelastine, azithromycin, bacitracin, beclomethasone dipropionate, bemegride, benazepril, benzilic acid, bendroflumethiazide, benzocaine, benzonatate, benzophenone, benzoyl peroxide, benztropine, bepridil, betamethasone dipropionate, betamethasone valerate, brimonidine, brompheniramine, bupivacaine, buprenorphine, bupropion, burimamide, butenafine, butoconazole, cabergoline, caffeic acid, caffeine, calcipotriene, camphor, candesartan cilexetil, capsaicin, carbamazepine, carbamide peroxide, cefditoren pivoxil, cefepime, cefpodoxime proxetil, celecoxib, cetirizine, cevimeline, chitosan, chlordiazepoxide, chlorhexidine, chloroquine, chlorothiazide, chloroxylenol, chloφheniramine, chlorpromazine, chlorpropamide, ciclopirox, cilostazol, cimetidine, cinacalcet, ciprofloxacin, citalopram, citric acid, cladribine, clarithromycin, clemastine, clindamycin, clioquinol, clobetasol propionate, clocortolone pivalate, clomiphene, clonidine, clopidogrel, clotrimazole, clozapine, cocaine, codeine, cromolyn, crotamiton, cyclizine, cyclobenzaprine, cycloserine, cytarabine, dacarbazine, dalfopristin, dapsone, daptomycin, daunorubicin, deferoxamine, dehydroepiandrosterone, delavirdine, desipramine, desloratadine, desmopressin, desoximetasone, dexamethasone, dexmedetomidine, dexmethylphenidate, dexrazoxane, dextroamphetamine, diazepam, diclofenac, dicyclomine, didanosine, dihydrocodeine, dihydromorphine, diltiazem, 6,8-dimercaptooctanoic acid (dihydrolipoic acid), diphenhydramine, diphenoxylate, dipyridamole, disopyramide, dobutamine, dofetilide, dolasetron, donepezil, dopa esters, dopamide, dopamine, dorzolamide, doxepin, doxorubicin, doxycycline, doxylamine, doxypin, duloxetine, dyclonine, econazole, efalizumab, eflornithine, eletriptan, emtricitabine, enalapril, ephedrine, epinephrine, epinine, epirubicin, eptifibatide, ergotamine, erythromycin, escitalopram, esmolol, esomeprazole, estazolam, estradiol, etanercept, ethacrynic acid, ethinyl estradiol, ethyl pyruvate, etidocaine, etomidate, famciclovir, famotidine, felodipine, fentanyl, ferulic acid, fexofenadine, flecainide, fluconazole, flucytosine, f(...)
法律状态
(WO2007103687) LEGAL DETAILS FOR WO2007103687  Actual or expected expiration date=2009-09-01    Legal state=DEAD    Status=LAPSED     Event publication date=2007-02-28  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2007062975  Application date=2007-02-28  Standardized application number=2007WO-US62975     Event publication date=2007-09-13  Event code=WO/A2  Event type=Examination events  International application published without international search report  Publication country=WO  Publication number=WO2007103687  Publication stage Code=A2  Publication date=2007-09-13  Standardized publication number=WO2007103687     Event publication date=2008-12-11  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2007103687  Publication stage Code=A3  Publication date=2008-12-11  Standardized publication number=WO2007103687     Event publication date=2009-09-01  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU2007223560  Actual or expected expiration date=2012-09-20    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2007223560  Application date in the designated or member state=2007-02-28   Application number in the designated or member state=2007AU-0223560 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2007223560  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2007-09-13   Publication number in the designated or member state=AU2007223560    Event publication date=2008-09-16  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=AU     Event publication date=2008-10-09  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=AU     Event publication date=2012-09-20  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE CA2644311  Actual or expected expiration date=2027-02-28    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2644311  Application date in the designated or member state=2007-02-28   Application number in the designated or member state=2007CA-2644311 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2644311  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2007-09-13   Publication number in the designated or member state=CA2644311    Event publication date=2008-08-29  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CA     Event publication date=2012-07-10  Event code=CA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2008-09-02    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2008-09-02  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP1998788  Actual or expected expiration date=2012-02-02    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=EP Corresponding appl: EP07757636  Application date in the designated or member state=2007-02-28   Application number in the designated or member state=2007EP-0757636 Corresponding cc:  Designated or member state=EP Corresponding pat: EP1998788  Publication stage code in the designated or member state=A2  Publication date in the designated or member state=2008-12-10   Publication number in the designated or member state=EP1998788    Event publication date=2007-11-14  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2012-08-08  Event code=EP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2027-02-28    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2008557487    Event publication date=2008-09-01  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=JP     Event publication date=2013-02-01  Event code=JP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE MX2008011236  Actual or expected expiration date=2027-02-28    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=MX Corresponding appl: MX2008011236  Application date in the designated or member state=2007-02-28   Application number in the designated or member state=2008MX-PA11236 Corresponding cc:  Designated or member state=MX Corresponding pat: MX2008011236  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2009-02-10   Publication number in the designated or member state=MX2008011236    Event publication date=2012-02-09  Event code=MX/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=MX
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部